{
  "file_metadata": {
    "text_file": "data/extracted_text/pdf_20250803_124126_860289_extracted_text.txt",
    "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
    "pdf_filename": "pdf_20250803_124126_860289.pdf",
    "file_size": 49585,
    "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
    "journal": "Advanced Therapeutics",
    "doi": "10.1002/adtp.202300344",
    "year": "2024",
    "title": "Charging Ahead: Examining the Future Therapeutic Potential of Electroceuticals",
    "confidence_score": null,
    "document_type": "review",
    "crossref_data": true,
    "enrichment_method": "crossref_api"
  },
  "chunks": [
    {
      "text": "Electroceuticals, derived from \"electronic\" and \"pharmaceuticals,\" aim to therapeutically manipulate neuronal signaling. Recent advancements have broadened the scope of electroceuticals, necessitating a revised framework that extends beyond neuron-targeted interventions. This review proposes a broader definition of electroceuticals, encompassing interventions targeting electrical signaling in various cell types, not just neurons, for therapeutic purposes. This framework categorizes electroceuticals based on their physiological level of action: cellular, tissue, organ, and systemic. The review discusses emerging developments and future directions for each category, highlighting the potential of electroceuticals in diverse areas like birth defects, oncology, neurodegeneration, and metabolic diseases.",
      "section": "Introduction",
      "topic": "Electroceuticals and Bioelectricity",
      "chunk_summary": "A revised framework for electroceuticals is proposed, expanding its scope beyond neuron-targeted interventions to encompass various cell types and physiological levels.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "The field of electroceuticals has evolved significantly since its inception. The nervous system's role in regulating bodily processes makes its modulation via electroceuticals a powerful therapeutic approach. Advancements in genetic, biochemical, and bioinformatics technologies have improved our understanding of neuronal communication. The emerging field of developmental bioelectricity has revealed the importance of ion-driven electrical communication in various cell types, opening new possibilities for interventions in diverse disease areas. Despite its potential, pharmaceutical companies have limitedly explored electroceuticals. Their involvement could be beneficial in clinical trial design, combination strategies with pharmaceuticals, and scaling validation and distribution of these innovative therapies.",
      "section": "Introduction",
      "topic": "Evolution of Electroceuticals",
      "chunk_summary": "The field of electroceuticals has evolved, driven by advancements in understanding neuronal communication and the role of bioelectricity, but requires greater pharmaceutical industry involvement.",
      "position_in_section": "Middle",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "This review proposes a revised ontology and framework for electroceuticals, incorporating recent developments in bioelectricity research. This aims to provide greater coherence and inclusivity to the field, moving beyond devices and neural targets. By exploring the scientific progress and outlining challenges, the review aims to broaden the application of electroceuticals to a wider range of diseases and encourage collaboration between academia and industry.",
      "section": "Introduction",
      "topic": "Revised Framework for Electroceuticals",
      "chunk_summary": "The review proposes a revised framework for electroceuticals to enhance coherence, inclusivity, and broader application in various disease areas.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Electroceuticals encompass established interventions like pacemakers and cochlear implants. Tracey and Tak's research on the vagal inflammatory reflex highlighted the potential for targeted electrical therapies. Examples include CVRx's Barostim for heart failure and SetPoint Medical's implant for rheumatoid arthritis. Given the growing complexity and applications, and the overlap with bioelectricity, a revised definition of electroceuticals is proposed.",
      "section": "Electroceuticals: The Need for a Revised Ontology and Framework",
      "topic": "Existing Electroceutical Therapies",
      "chunk_summary": "Existing electroceutical therapies like pacemakers and vagal nerve stimulation demonstrate the potential of this field, but a revised definition is needed to encompass its expanding scope.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "A revised ontology for electroceuticals offers several benefits: aligning terminology and definitions, and broadening the scope beyond neuron-targeted devices. The term \"electroceuticals\" is often used interchangeably with other terms, creating ambiguity.  Electrical signaling governs processes beyond neuronal tissues, necessitating recognition of broader applications. Non-neuronal cellular interfaces, ion-channel-targeting compounds, and optogenetic approaches should also be considered within the electroceuticals framework.",
      "section": "Electroceuticals: The Need for a Revised Ontology and Framework",
      "topic": "Benefits of a Revised Ontology",
      "chunk_summary": "A revised ontology clarifies terminology, expands the scope beyond neurons, and includes non-device based approaches.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "The proposed revised definition of electroceuticals is: \"the use of a therapeutic intervention to treat or prevent disease through the alteration of electrical signals in excitable or nonexcitable cells.\" This definition encompasses various therapeutic interventions, including drugs, devices, and future modalities. It covers a range of therapeutic benefits, from symptomatic relief to disease modification and prevention. The targets include both excitable and nonexcitable cells, and \"alteration\" covers various modifications like stimulation, inhibition, and normalization.",
      "section": "Re-Defining Electroceuticals",
      "topic": "Revised Definition of Electroceuticals",
      "chunk_summary": "Electroceuticals are redefined as therapeutic interventions altering electrical signals in any cell type to treat or prevent disease.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Presenting new results",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "A proposed ontology for bioelectric research categorizes interventions based on the physiological level targeted: cellular, tissue, organ, and systemic. At each level, non-device driven approaches manipulating bioelectric signaling are termed \"bioelectroceuticals,\" while exogenous electrical stimuli via devices are termed \"bioelectronic medicine\" or BEM.",
      "section": "Re-Defining Electroceuticals",
      "topic": "Proposed Ontology for Bioelectric Research",
      "chunk_summary": "Bioelectric research is categorized into cellular, tissue, organ, and systemic levels, with interventions classified as bioelectroceuticals or bioelectronic medicine based on device usage.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Presenting new results",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Cellular level bioelectric signaling involves inter- and intracellular electrical signaling mediated by changes in resting membrane potential (Vmem). Ion flow across the plasma membrane governs Vmem, and bioelectrical signals from ion channels are transduced into secondary messenger responses, affecting cell behavior. Organelle-level bioelectric signaling, mediated by intracellular cascades, is essential for organelle homeostasis.  Alternating electric fields can degrade protein aggregates in Alzheimer's disease and trigger apoptosis in cancer cells.",
      "section": "Cellular Level Bioelectric Signaling",
      "topic": "Cellular Bioelectricity",
      "chunk_summary": "Cellular bioelectric signaling, involving changes in Vmem and ion flow, influences cell behavior and organelle homeostasis, with potential applications in diseases like Alzheimer's and cancer.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Applications of cellular level bioelectric signaling include stem cell control and cancer treatment.  Endogenous electrical signaling plays a role in stem cell proliferation and differentiation.  Exogenous electrical stimulation (EStim) can influence stem cell fate in vitro and in vivo, offering a novel way to control stem cell behavior for regenerative medicine. Misregulation of ion channels and Vmem is linked to cancer. Cancer cells have depolarized Vmem compared to normal cells.  Modulating bioelectric properties, such as using ion-channel modulators (cellular bioelectroceuticals), shows promise in cancer treatment.",
      "section": "Cellular Level Bioelectric Signaling",
      "topic": "Applications of Cellular Bioelectricity",
      "chunk_summary": "Cellular bioelectric signaling has applications in stem cell control and cancer treatment, with potential for regenerative medicine and novel cancer therapies.",
      "position_in_section": "Middle",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Challenges in translating cellular bioelectric signaling to the clinic include incomplete biological understanding, lack of high-throughput screens and relevant models, and difficulty in locally targeting bioelectricity modulation.  Key questions remain about the molecular mechanisms, cell-type specific effects, and appropriate models for studying bioelectricity.  Developing robust methods for studying cellular bioelectroceuticals and screening for Vmem-altering compounds is crucial.  Selective modulation of diseased or stem cell Vmem, determining the appropriate ion channel targets, and understanding the effects of Vmem changes on cell fate are important considerations.",
      "section": "Cellular Level Bioelectric Signaling",
      "topic": "Challenges in Cellular Bioelectricity",
      "chunk_summary": "Translating cellular bioelectric signaling faces challenges in understanding mechanisms, developing appropriate models and screening methods, and achieving targeted modulation of Vmem.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Tissue-level bioelectric signaling involves inherent electrical signals that vary depending on the tissue's state (development, injury, disease, or health). External electrical stimuli can alter tissue development and healing.  Applications include wound healing, tumor treatment, and engineered tissue. In wound healing, an endogenous electrical field guides cell migration (electrotaxis).  Tumor-treating electrical fields (TTFields) disrupt cancer cell proliferation and stimulate apoptosis.  Electrical signaling can improve tissue engineering, promoting structural organization and function in engineered tissues like cardiac tissue and bone.",
      "section": "Tissue Level Bioelectric Signaling",
      "topic": "Tissue Bioelectricity",
      "chunk_summary": "Tissue-level bioelectric signaling plays a role in development, healing, and disease, with applications in wound healing, tumor treatment, and tissue engineering.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "While clinical data from tissue-level bioelectric signaling applications like Procellera and Optune are promising, further exploration is needed.  A better understanding of cellular responses to EStim is crucial for optimizing its application.  Standardization and improvement of therapeutic EStim protocols and devices are also necessary.",
      "section": "Tissue Level Bioelectric Signaling",
      "topic": "Challenges in Tissue Bioelectricity",
      "chunk_summary": "Despite promising clinical data, further research and standardization are needed to optimize and broaden the application of tissue-level bioelectric signaling.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Organ-level bioelectric signaling involves electrical communication through peripheral nerves connecting organs to the central nervous system and other organs. Organ-level BEMs address dysfunction in this signaling using electronic devices.  These BEMs can be classified as \"broad\" or \"precise\" based on their specificity. Broad BEMs deliver non-targeted electrical pulses to manage symptoms in chronic conditions like pain and tremor. Examples include TENS, SCS, and DBS.  Precise BEMs deliver targeted pulses to trigger specific biological mechanisms, such as modulating the inflammatory reflex to treat autoimmune diseases or stimulating cardiovascular reflexes.",
      "section": "Organ Level Bioelectric Signaling",
      "topic": "Organ-Level Bioelectricity",
      "chunk_summary": "Organ-level bioelectric signaling uses BEMs, classified as broad or precise, to modulate nerve signaling and treat conditions like pain, tremor, and autoimmune diseases.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Challenges for organ-level BEMs include incomplete understanding of disease biology and mechanisms of action, evidence requirements and controls, and distinguishing therapeutic effects from safety concerns.  A better understanding of neural control of diseases and the MoA of BEMs is crucial for target validation and clinical progression.  Rigorous clinical trials with appropriate controls are needed to determine true treatment effects.  Variations in patient responses and stimulation parameters require careful assessment to optimize treatment and ensure safety.  Key questions remain about treatment effect size, predictive biomarkers, optimization of treatment parameters, and the potential for tachyphylaxis.",
      "section": "Organ Level Bioelectric Signaling",
      "topic": "Challenges in Organ-Level Bioelectricity",
      "chunk_summary": "Translating organ-level BEMs faces challenges in understanding disease biology and MoA, designing rigorous clinical trials, and optimizing treatment parameters for efficacy and safety.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "Systems-level bioelectric signaling involves voltage gradients that specify information like axial polarity, patterning, and organ identity during development, remodeling, and regeneration.  A morphogenetic code, including bioelectricity, regulates large-scale changes by controlling gene expression and cell behaviors.  Studies in planaria and Xenopus demonstrate the ability to manipulate bioelectric patterns to alter regeneration and induce ectopic organs.  Bioelectric signaling differs from traditional ion channel biology in that it focuses on spatial voltage gradients rather than individual ion channels.  Exogenous EStim can improve regeneration, mimicking biophysical processes in regenerative species.",
      "section": "Systems Level Bioelectric Signaling",
      "topic": "Systems Bioelectricity",
      "chunk_summary": "Systems-level bioelectric signaling involves voltage gradients that regulate large-scale changes in development and regeneration, offering potential for manipulating morphogenesis.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "The main challenge in systems-level bioelectric signaling is its nascent stage of research.  A deeper understanding of the bioelectric code, its mapping to downstream changes, and its role in developmental and regenerative biology is needed.  Further research is crucial to unlock the full potential of manipulating bioelectric properties for therapeutic purposes.",
      "section": "Systems Level Bioelectric Signaling",
      "topic": "Challenges in Systems Bioelectricity",
      "chunk_summary": "The nascent stage of research in systems-level bioelectric signaling poses a major challenge, requiring further investigation to understand its therapeutic potential.",
      "position_in_section": "End",
      "certainty_level": "High",
      "citation_context": "Describing prior work",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    },
    {
      "text": "The future of electroceuticals requires collaboration across the life science ecosystem.  Progress in all levels of electroceutical research necessitates collaboration between academia, innovators, biotech, pharma, regulators, and healthcare systems.  Electroceuticals hold promise for disease treatment, tissue and organ regeneration, and even alleviating aging effects.  Commercial viability depends on selecting diseases with high unmet need, demonstrating improved efficacy and safety, maintaining patient convenience, securing patent life, ensuring scalability, and addressing pricing and reimbursement challenges.  A better understanding of bioelectricity's rules and molecular mechanisms is crucial to maximize the potential of this field.",
      "section": "Outlook",
      "topic": "Future of Electroceuticals",
      "chunk_summary": "The future of electroceuticals relies on collaboration across the life science ecosystem to address research and translational challenges and unlock its full therapeutic potential.",
      "position_in_section": "Beginning",
      "certainty_level": "High",
      "citation_context": "Drawing conclusions",
      "page_number": null,
      "pdf_filename": "pdf_20250803_124126_860289.pdf",
      "original_filename": "pdf_20250803_124126_860289_extracted_text.txt",
      "authors": "[\"Swarnalatha Balasubramanian\", \"David A. Weston\", \"Michael Levin\", \"Devon Charles Cardoso Davidian\"]",
      "year": "2024",
      "journal": "Advanced Therapeutics",
      "doi": "10.1002/adtp.202300344"
    }
  ],
  "gemini_response": "",
  "processed_at": "2025-08-06T12:15:42.959028",
  "enriched_at": "2025-08-11T14:28:57.020416",
  "enrichment_methods": [
    "crossref"
  ]
}